Henry Ford Health

Henry Ford Health Scholarly Commons
Hematology/Oncology Articles

Hematology-Oncology

8-1-2022

Lung Cancer Screening Criteria and Cardiopulmonary
Comorbidities
Chan Yeu Pu
Christine M. Lusk
Christine Neslund-Dudas
Shirish M. Gadgeel
Ayman O. Soubani

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/
hematologyoncology_articles

Authors
Chan Yeu Pu, Christine M. Lusk, Christine Neslund-Dudas, Shirish M. Gadgeel, Ayman O. Soubani, and Ann
G. Schwartz

ORIGINAL ARTICLE

Lung Cancer Screening Criteria and
Cardiopulmonary Comorbidities
Chan Yeu Pu, MD, MS,a,b,* Christine M. Lusk, MPH,b,c
Christine Neslund-Dudas, PhD,d,e Shirish Gadgeel, MD,e Ayman O. Soubani, MD,a,b
Ann G. Schwartz, MPH, PhDb,c
a

Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine, Detroit, Michigan
Karmanos Cancer Institute, Detroit, Michigan
c
Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan
d
Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan
e
Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan
b

Received 21 March 2022; revised 12 June 2022; accepted 29 June 2022
Available online - 4 July 2022

ABSTRACT
Introduction: Lung cancer screening criteria should select
candidates with minimal cardiopulmonary comorbidities
who are ﬁt for curative lung cancer resection.
Methods: We retrospectively analyzed 728 patients with
lung cancer for screening eligibility using the U.S. Preventive Services Task Force (USPSTF) 2013 criteria (n ¼ 370).
If ineligible for screening, they were further assessed for
eligibility using the USPSTF 2021 (n ¼ 121) and National
Comprehensive Cancer Network group 2 (NCCN gp 2) (n ¼
155). Comparisons of cardiopulmonary comorbidities between patients selected by the different lung cancer
screening criteria were performed. Excluding missing data,
a similar comparison was done between USPSTF 2013 (n ¼
283) and PLCOm2012 (risk threshold 1.51%) (n ¼ 118).
Results: Patients eligible for USPSTF 2021 and NCCN gp 2
had lower rates of airﬂow obstruction (forced expiratory
volume in 1 s [FEV1]/forced vital capacity <0.7) compared
with those in USPSTF 2013 (55.4% and 56.8% versus
70.5%). Both USPSTF 2021 and NCCN gp 2 groups had less
severe airﬂow obstruction; only 11.6% and 12.9% of patients, respectively, had percent-predicted FEV1 less than
50% versus 20.3% in the USPSTF 2013 group. Comparing
USPSTF 2013 and PLCOm2012 revealed no signiﬁcant differences in age or the rate of airﬂow obstruction (p ¼ 0.06
and p ¼ 0.09 respectively). Nevertheless, rates of percentpredicted FEV1 less than 50% and diffusing capacity of
the lungs for carbon monoxide less than 50% were lower in
the PLCOm2012 group compared with those in the USPSTF
2013 group (22.3% versus 10.2% and 32.6% versus
20.0%), respectively.
Conclusions: The USPSTF 2021 qualiﬁes an additional group
of screening candidates who are healthier with better lung

reserve, translating to better surgical candidacy but potentially more overdiagnosis. The PLCOm2012, with its better
accuracy in selecting patients at risk of cancer, selects an
older group with chronic obstructive pulmonary disease but
with good lung reserve and potentially less overdiagnosis.
 2022 The Authors. Published by Elsevier Inc. on behalf of
the International Association for the Study of Lung Cancer.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Lung cancer screening; Pulmonary comorbidities;
USPSTF 2013; USPSTF 2021; PLCOm2012

Introduction
The goal of lung cancer screening is to detect lung
cancer at an early stage to allow for curative lung cancer
resection. Hence, selection of a good surgical candidate is
an important factor for determining the effectiveness of
lung cancer screening criteria. The old U.S. Preventive
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Services Task Force (USPSTF) 2013 and the new USPSTF
2021 are ﬁxed criteria on the basis of age and pack years
smoked.1,2 In contrast, PLCOm2012 is a predictive model
risk-based criterion taking into account additional risk
factors in deciding screening eligibility.3
The USPSTF in 2021 broadened its lung cancer
screening criteria to include younger patients and lower
smoking pack years (adults aged 50–80 y with 20 packyear smoking history) whereas the USPSTF 2013
recommendation targets an older cohort of adults with
higher smoking pack years (aged 55–80 y with 30 packyear history). The USPSTF 2013 criteria are similar to
the National Lung Cancer Screening Trial (NLST)/National Comprehensive Cancer Network group 1 (NCCN
gp 1) and the Centers for Medicare and Medicaid Services, which differs only in the upper age limit being 74
and 77 years old, respectively, which makes it one of the
mostly widely used and endorsed criteria.4,5 The most
recent USPSTF 2021 criteria allow for a younger group
of patients with potentially lower cardiopulmonary comorbidity to beneﬁt from lung cancer screening.
The PLCOm2012 model is the most studied prediction
model6 and was recommended by the NCCN in 2018 as an
alternative guideline for patient enrollment into lung
screening if they do not fulﬁll the ﬁxed criteria.7 It has
been suggested that the PLCOm2012 is more sensitive but
equally speciﬁc compared with USPFT 2013 for lung
cancer detection.3 Increasing age, smoking rate, personal
history of cancer, family history of lung cancer, race, education level, and body mass index all contribute to the
risk threshold for screening using the PLCOm2012 model
rather than being limited to age and smoking exposure.
This can potentially allow for patients with increased
cancer risk but without the concurrent increased comorbidity and surgical risk. The NCCN introduced the NCCN
gp 2 criteria which are also ﬁxed criteria on the basis of
the age and smoking pack-year requirements similar to
USPSTF 2021 but with additional risk factor requirements
similar to the variables from the PLCOm2012.7
The risk for cancer and the risk of surgery are a
double-edged sword. The higher pack-year requirement
for screening eligibility not only recognizes those with
higher lung cancer risk but also results in higher rates of
pulmonary and cardiac comorbidities.8 In the NLST, the
presence of chronic obstructive pulmonary disease
(COPD) doubled the lung cancer incidence.9 The risk of
postoperative complication increases by 10% for every
5% decrement in lung function.10 The severity of COPD
is determined by the patients’ pulmonary function test
(PFT) results, especially forced expiratory volume in 1
second (FEV1) and diffusing capacity of the lungs for
carbon monoxide (DLCO).
To assess candidacy for lung resection based on PFT,
predicted postoperative (PPO) FEV1 and DLCO are
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calculated using the following formula: PPO ¼ preoperative FEV1  (1 – y/z) where y is the estimated number
of lung segments to be removed and z is the total
number of lung segments which is 19.11 When lobectomy is performed for lung cancer, the number of segments removed will depend on which lobe is involved.
There are three, two, and ﬁve segments in the right
upper, middle, and lower lobe, respectively. On the left
lung, there are ﬁve and four segments in the upper and
lower lobe, respectively. Hence, a lung screening patient
should expect to lose 10% to 26% (2–5 lobes) of their
lung function if they undergo at least a lobar resection
from a positive screening.
With the newly published USPSTF 2021 criteria and
the more dynamic predictive model risk-based
PLCOm2012, it is crucial to compare the cardiopulmonary comorbidities of patients selected by these criteria
compared with the long-established USPSTF 2013. The
aims of our study are to compare the USPSTF 2013
criteria to USPSTF 2021, NCCN gp 2, and PLCOm2012
predictive model risk-based criteria and to evaluate
cardiopulmonary comorbidities and surgical candidacy
of patients selected.

Materials and Methods
We retrospectively analyzed data from the eversmoking participants with lung cancer recruited for the
INﬂammation, Health, Ancestry and Lung Epidemiology
(INHALE) study.12,13 Brieﬂy, participants from the general metropolitan Detroit area with lung cancer were
enrolled at the Karmanos Cancer Institute or Henry Ford
Health System (HFHS) within 12 months of diagnosis,
between May 2012 and March 2018 at Karmanos Cancer
Institute and between May 2012 and November 2014 at
HFHS. They were 21 to 89 years of age at diagnosis and
were able to complete a PFT with no prior lung cancer
diagnosis or lung resection. Informed consent was obtained from all participants.

Data Collection
Interviews were conducted with patients to obtain
their demographic information, past medical history
(cancer, COPD, cardiovascular disease [CVD]), environmental exposures, and detailed smoking history. Patients
either completed PFT on enrollment or had their PFT
data abstracted from electronic medical record closest to
the date of enrollment. The percent-predicted FEV1 and
forced vital capacity (FVC) were calculated on the basis
of sex, age, height, and race with reference values on the
basis of the Third National Health and Nutrition Examination Survey. The PFT was reviewed by board-certiﬁed
pulmonologists blinded to the study. Patients’ cancer
outcomes (stage, histology) were abstracted from either
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Figure 1. Patient selection for comparison between USPSTF 2013 with other ﬁxed criteria and prediction model risk-based
criteria using the INHALE patient cohort. *Additional risk factors include the following: cancer history, family history of
lung cancer, radon exposure, occupational exposure (silica, cadmium, asbestos, arsenic, beryllium, chromium (VI), diesel
fumes, and nickel, COPD, and pulmonary ﬁbrosis). COPD, chronic obstructive pulmonary disease; INHALE, INﬂammation,
Health, Ancestry and Lung Epidemiology; NCCN, NCCN gp2, National Comprehensive Cancer Network; PFT, pulmonary
function test; USPSTF, U.S. Preventive Services Task Force.

the electronic medical record or the Metro Detroit Cancer Surveillance System population-based cancer registry. Institutional review board approvals were obtained
from both Wayne State University and HFHS, and
informed consent was obtained for all participants.

Comparison Between the Lung Cancer Screening
Criteria
We assessed patients’ eligibility for lung cancer
screening sequentially using different eligibility criteria,
starting with the USPSTF 2013 criteria as found in
Figure 1. If they did not qualify, they then were assessed
for eligibility using other ﬁxed criteria under the USPSTF
2021 and the NCCN gp 2 guidelines and under the
prediction model risk-based criteria of PLCOm2012
(risk threshold >1.51%/6 y) (Fig. 1). Using USPSTF
2013 as the reference, comparisons were made between
patients who did not qualify for USPSTF 2013 but
qualiﬁed under the ﬁxed criteria USPSTF 2021 and
NCCN gp 2. In the USPSTF 2013 comparison with the
prediction model risk-based criteria, patients were
excluded for missing education data needed to calculate
the PLCOm2012 risk score.

Comparisons were made between patients eligible for
each criterion with regard to their age, smoking pack
years, PFTs, and cardiopulmonary comorbidities. History
of CVD included self-reported stroke, arrhythmia, and
congestive heart failure. Presence of airﬂow obstruction
was deﬁned as FEV1/FVC less than 0.7 per the GOLD
criteria for COPD.14 Patients’ PFTs were compared with
regard to presence of FEV1 less than 50%, DLCO less
than 50%, and FEV1/FVC less than 0.7. History of COPD
was based on patient self-report, whereas “any COPD”
was based on their self-report or FEV/FVC less than 0.7.

Statistical Analysis
Continuous measures were reported as means and
SDs and categorical data in frequencies and percentages.
All statistical analyses were performed using either SAS
version 9.4 or R version 4.1.1 with statistical signiﬁcance
set at p less than 0.05. Group comparisons were performed using t tests and chi-square tests as indicated.

Results
There were 728 patients with lung cancer from the
INHALE cohort with PFT results who were assessed
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Table 1. Description of 728 Ever-Smoker Lung Cancer Cases
With PFT Data
Variables

n (%)

Age (y), mean (SD)
Age (y)
<50
50–59
60–69
70–79
80
Sex
Male
Female
Race
White
African American
Pack-years, mean (SD)
Pack-years
<10
10–19
20–29
30
Smoking status
Former
Current
Quit time (former smokers), mean (SD)
Quit time (former smokers)
<15
15
Comorbidities
Cardiovascular diseasea
COPD
Diabetes
Hypertension
% Pred FEV1%, mean (SD)
% Pred DLCO %, mean (SD)
Personal history of cancer
No
Yes
Family history of cancer
No
Yes
BMI
Underweight (<18.5 kg/m2)
Normal (18.5–24.9 kg/m2)
Overweight (25–29.9 kg/m2)
Obese (30 kg/m2)
Missing
Education
Less than 12 y
High school diploma (12 y)
More than 12 y
Missing
Histology
Squamous cell carcinoma
Small cell carcinoma
Adenocarcinoma
NSCLC (other)
Unknown/missing

64.5 (9.5)
45 (6.2)
179 (24.6)
273 (37.5)
190 (26.1)
41 (5.7)
316 (43.4)
412 (56.6)
455 (62.5)
273 (37.5)
46.4 (28.5)
34 (4.7)
81 (11.2)
104 (14.3)
507 (69.8)
424 (58.2)
304 (41.8)
11.5 (12.8)
134 (18.4)
594 (81.6)
188 (27.5)
293 (41.9)
98 (17.9)
394 (57.3)
73.0 (21.8)
62.8 (19.8)
559 (77.0)
167 (23.0)
225 (30.9)
503 (69.1)
30 (4.8)
233 (37.5)
189 (30.4)
169 (27.2)
107
95 (17.3)
222 (40.4)
232 (42.3)
179
203 (28.0)
65 (9.0)
413 (57.0)
44 (6.0)
3 (0.0)
(continued)

Vol. 3 No. 8

Table 1. Continued
Variables
Stage
I
II
III
IV
Unknown/missing
Treatment
Radiation
Chemo
Surgery

n (%)
220
108
187
211
2

(30.3)
(14.9)
(25.8)
(29.0)

348 (49.4)
343 (54.3)
288 (39.6)

Note: Measures presented as n (%) unless otherwise noted.
a
Self-reported stroke, arrhythmia, and congestive heart failure.
% pred, percent-predicted; BMI, body mass index; COPD, chronic obstructive
pulmonary disease; DLCO, diffusing capacity of the lungs for carbon monoxide; FEV1, forced expiratory volume in 1 second; PFT, pulmonary function
test.

sequentially for screening eligibility. They had a mean ±
SD age of 64.5 ± 9.5 years, with more females than males
(56.6% versus 43.4%) and the racial majority was White
(62.5%) with the remaining 37.5% African American
(Table 1). In terms of smoking burden, 69.8% were
smokers with more than 30 pack-years and 41.8% of the
patients were current smokers. History of CVD was
present in 27.5% of the patients. They had a mean
percent-predicted FEV1 and DLCO of 73.0 ± 21.8 and
62.8 ± 19.8, respectively. Adenocarcinoma (57.0%) was
the most common cancer histology followed by squamous cell carcinoma (28.0%). In terms of treatment,
49.4%, 54.3%, and 39.6% of the patients received radiation, chemotherapy, and surgery, respectively.
Starting with the USPSTF 2013 reference group, 370
of patients qualiﬁed. The remaining patients were
assessed for both USPSTF 2021 and NCCN gp 2 criteria,
of which 121 and 155 patients qualify for screening
under each set of criteria, respectively. For the comparison with the PLCOm2012 criteria, all patients with
missing education data needed for PLCOm2012 risk
calculation were excluded, leaving 283 patients in the
USPSTF 2013 group. The rest of the patients were
assessed for PLCOm2012 eligibility of whom 118 patients qualiﬁed.
The ﬁxed criteria comparisons using USPSTF 2013
criteria as reference versus USPSTF 2021 and NCCN gp 2
criteria are found in Table 2. The mean age of patients in
the USPSTF 2013 group was 66.0 ± 6.3, which was
similar to the NCCN gp 2 group (66.0 ± 11.0) and the
USPSTF 2021 group was signiﬁcantly younger (59.6 ±
9.0). The USPSTF 2013 group had the heaviest pack
years smoked at 62.1 ± 25.9 compared with 40.5 ± 20.4
in the NCCN gp 2 group and 36.2 ± 19.8 in the USPSTF
2021 group. The proportions of smokers with pack-years
20 to 29 were 55.4% and 38.1% in the USPSTF 2021
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Table 2. Pulmonary Comorbidity Measures in INHALE Ever-Smoker Lung Cancer Cases Who Were Either Eligible for USPSTF
2013 or USPSTF 2021 and NCCN Group 2 (N ¼ 561)
Variable
Age, mean (SD)
Pack-years, mean (SD)
Pack-years
<20
20–29
30
History of CVD
No
Yes
FEV1/FVC <0.7
No
Yes
% pred FEV1 <50%
No
Yes
% pred DLCO <50%
No
Yes
History of COPD
No
Yes
Any COPDa
No
Yes

USPSTF 2013
N ¼ 370

USPSTF 2021
N ¼ 121

p (USPSTF 2013
vs. 2021)

NCCN group 2
N ¼ 155

p (USPSTF 2013 vs.
NCCN group 2)

66.0 (6.3)
62.1 (25.9)

59.6 (9.0)
36.2 (19.8)

<0.01
<0.01

66.0 (11.0)
40.5 (20.4)

0.97
<0.01

0
0
370 (100.0)

0
67 (55.4)
54 (44.6)

<0.01

0
59 (38.1)
96 (61.9)

<0.01

239 (69.1)
107 (30.9)

88 (75.9)
28 (24.1)

0.16

104 (71.7)
41 (28.3)

0.56

109 (29.5)
261 (70.5)

54 (44.6)
67 (55.4)

<0.01

67 (43.2)
88 (56.8)

<0.01

295 (79.7)
75 (20.3)

107 (88.4)
14 (11.6)

0.03

135 (87.1)
20 (12.9)

0.05

214 (70.9)
88 (29.1)

86 (81.1)
20 (18.9)

0.04

99 (77.9)
28 (22.1)

0.13

177 (49.4)
181 (50.6)

74 (62.7)
44 (37.3)

0.01

85 (55.9)
67 (44.1)

0.18

76 (20.5)
294 (79.5)

40 (33.1)
81 (66.9)

<0.01

49 (31.6)
106 (68.4)

0.01

Either self-reported history of COPD or FEV1/FVC <0.7 on spirometry.
% pred, percent-predicted; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity of the lungs for carbon monoxide; FEV1, forced expiratory
volume in 1 second; FVC, forced vital capacity; INHALE, INﬂammation, Health, Ancestry and Lung Epidemiology; NCCN, National Comprehensive Cancer
Network; USPSTF, U.S. Preventive Services Task Force. Frequencies presented as N (%).
a

group and the NCCN gp 2 group, respectively. History of
CVD was present in 30.9% of the USPSTF 2013 patients
and was lower in the NCCN gp 2 group and the USPSTF
2021 group, at 28.3% and 24.1%, respectively, but these
differences were not statistically signiﬁcant. Airway
obstruction deﬁned as FEV1/FVC less than 0.7 was
present in 70.5% of the patients in USPSTF 2013 which
was signiﬁcantly higher compared with 55.4% and
56.8% in USPSTF 2021 and NCCN gp 2, respectively. We
measured the severity of airﬂow obstruction by evaluating the FEV1. The number of patients with FEV1 less
than 50% was almost double and statistically higher in
the USPSTF 2013 group at 20.3% compared with 11.6%
and 12.9% in the USPSTF 2021 group and the NCCN gp 2
group, respectively. Similarly, the number of patients
with DLCO less than 50% was 29.1% in the USPSTF
2013 group which was signiﬁcantly higher than 18.9%
in the USPSTF 2021 group but not statistically signiﬁcant
when compared with 22.1% in the NCCN gp 2 group.
Figure 2A and B illustrates the distribution of FEV1 and
DLCO (in 10% increments) among patients selected by
the different screening criteria. History of COPD based
on patient’s self-reporting was present in 50.6% of patients in the USPSTF 2013 group which was signiﬁcantly

higher than that of 37.3% in the USPSTF 2021 group but
not signiﬁcantly different compared with 44.1% in the
NCCN gp 2 group. Presence of COPD based on either
spirometry or self-reporting (any COPD) was 79.5% in
the USPSTF 2013 group, which was signiﬁcantly higher
than 66.9% and 68.4% in the USPSTF 2021 group and
the NCCN gp 2 group, respectively.
The prediction model risk-based criteria comparison
consisted of 283 patients in the USPSTF 2013 group
versus 118 patients in the PLCOm2012 group. Patients
in the PLCOm2012 were of similar age compared with
patients in the USPSTF 2013 group (67.6 ± 10.6 versus
65.7 ± 6.1, p ¼ 0.06) (Table 3). Only half of the patients
in the PLCOm2012 group were smokers of 30 pack-years
and above. The mean pack-year was signiﬁcantly lower
in the PLCOm2012 group compared with the USPSTF
2013 group (38.8 ± 21.8 versus 59.8 ± 22.9, p < 0.01).
History of CVD was present in 29.7% and 30.5% of patients in the USPSTF 2013 group and the PLCOm2012
group, respectively, which was not statistically different.
Airway obstruction (FEV1/FVC < 0.7) was present in
68.9% of patients in the USPSTF 2013 group and was
lower in the PLCOm2012 group at 60.2% but was not
statistically signiﬁcant. In terms of severity of airﬂow
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Figure 2. Pulmonary function test results for patients selected by different lung screening criteria. (A) Percent-predicted
FEV1 distribution and (B) percent-predicted DLCO distribution. Grouping of patients per Table 2: USPSTF 2013, n ¼ 370;
NCCN gp2, n ¼ 155; USPSTF 2021, n ¼ 121. DLCO, diffusing capacity of the lungs for carbon monoxide; FEV1, forced expiratory volume in 1 second; NCCN gp2, National Comprehensive Cancer Network group 2; USPSTF, U.S. Preventive Services
Task Force.

obstruction, the USPSTF 2013 group had twice the
number of patients with percent-predicted FEV1 less
than 50% than PLCOm2012 (22.3% versus 10.2%, p <
0.02). The USPSTF 2013 group also had signiﬁcantly
more patients with DLCO less than 50% compared with
PLCOm2012 (32.6% versus 20.0%, p ¼ 0.01). There
were no signiﬁcant differences between the USPSTF
2013 group and the PLCOm2012 group in the number of
patients having COPD based on self-report or spirometry
(history of COPD or any COPD).

Discussion
Our analysis described the cardiopulmonary comorbidities of patients selected by the original USPSTF 2013
versus additional patients selected by the newer USPSTF
2021 with a lower age and smoking threshold. As expected, a younger and healthier cohort of patients was
selected with better lung function and lower rates of
COPD which will likely be associated with better surgical
outcomes. The NCCN gp 2, which has the same age
and smoking requirement as USPSTF 2021 but with
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Table 3. Pulmonary Comorbidity Measures in INHALE Ever-Smoker Lung Cancer Cases Who Were Either Eligible for USPSTF
2013 or PLCO 2012 (N ¼ 401)
Variables
Age, mean (SD)
Pack-years, mean (SD)
Pack-years
<20
20–29
30
History of CVD
No
Yes
FEV1/FVC < 0.7
No
Yes
% pred FEV1 < 50%
No
Yes
% pred DLCO < 50%
No
Yes
History of COPD
No
Yes
Any COPDa
No
Yes

USPSTF 2013
N ¼ 283

PLCOm2012
N ¼ 118

p (USPSTF 2013
vs. PLCOm2012)

65.7 (6.1)
59.8 (22.9)

67.6 (10.6)
38.8 (21.8)

0.06
<0.01

0
0
283 (100.0)

11 (9.3)
43 (36.4)
64 (54.2)

<0.01

199 (70.3)
84 (29.7)

82 (69.5)
36 (30.5)

0.87

88 (31.1)
195 (68.9)

47 (39.8)
71 (60.2)

0.09

220 (77.7)
63 (22.3)

106 (89.8)
12 (10.2)

<0.01

149 (67.4)
72 (32.6)

76 (80.0)
19 (20.0)

0.02

151 (53.4)
132 (46.6)

73 (61.9)
45 (38.1)

0.12

68 (24.0)
215 (76.0)

34 (28.8)
84 (71.2)

0.32

Note: Frequencies presented as N (%).
a
Either self-reported history of COPD or FEV1/FVC <0.7 on spirometry.
% pred, percent-predicted; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; FEV1, forced expiratory volume in 1 second; FVC,
forced vital capacity; INHALE, INﬂammation, Health, Ancestry and Lung Epidemiology; USPSTF, U.S. Preventive Services Task Force.

additional risk factor requirements such as COPD, has
similarly good PFT results as USPSTF 2021. Nonetheless,
the rate of self-reported COPD was closer to the group
deﬁned under the USPSTF 2013. Comparison of the
USPSTF 2013 with the prediction model risk-based
criteria PLCOm2012 found that the PLCOm2012 in our
cohort also selected an equally older aged group of patients with similar COPD burden as USPSTF 2013.
Nonetheless, they have better lung reserve evidenced by
lower rates of FEV1 or DLCO less than 50%.
Even with mild COPD, patients have a higher prevalence of postoperative complications compared with
patients with normal spirometry results.15 Common
postoperative complications include pneumonia, atelectasis, prolonged air leak, empyema, and need for tracheostomy. Post hoc analysis of the NLST revealed that
mortality reduction with LDCT screening in participants
with COPD was only half of the mortality reduction in
participants without COPD (15% versus 28%, respectively).9,16 This may be due to competing causes of death,
such as CVD. In our cohort, the heavy smoking burden
required by the USPSTF 2013 selected almost 80% of
patients with COPD compared with the lower proportion
in USPSTF 2021 and NCCN gp 2 (66%–67%).

Nonetheless, among patients with COPD, it is more
beneﬁcial to screen patients with milder COPD than
more severe COPD. The study by de-Torres et al.17
revealed that LDCT screening in mild to moderate
COPD results in early, curable stages and better longterm survival. In contrast, other competing causes of
death inherent to COPD increase with worsening airﬂow
obstruction.18 We found that although USPSTF 2013 and
PLCOm2012 select patients very differently (ﬁxed
criteria versus prediction risk model based), both
criteria select patients with similar age and similar
proportion of having COPD. The difference here is the
severity of airﬂow obstruction (FEV1); the USPSTF 2013
selected double the number of patients with FEV1 less
than 50% compared with PLCOm2012 (20.3% versus
11.6%). This is also reﬂected in the number of patients
with DLCO less than 50%. Although the patients in
PLCOm2012 are of similar age, half of the group had less
than 30 pack-years of smoking. The International Lung
Screening Trial comparing the USPSTF 2013 versus
PLCOm2012 in screening eligibility found that the
PLCOm2012-selected patients were older and had more
comorbidities.19 The difference in ﬁnding can be attributed to the International Lung Screening Trial study only
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including patients aged 55 to 80 years for the
PLCOm2012 group when the PLCOm2012 can identify
additional high-risk patients outside of this age range.
A lung cancer-screening patient should expect to lose
10% to 26% (2–5 lobes) of their lung function if they
undergo at least a lobar resection from a positive
screening result. We selected 50% prediction as the
cutoff for evaluating our patients’ FEV1 and DLCO
because that will give a PPO value of 40%, assuming
20% loss in lung function. In-hospital mortality has been
reported to be 14% in patients with PPO FEV1 less than
40%.20 Patients found to have lung cancer by screening
tend to be of early stage. Among patients with stage 1
NSCLC and COPD, patients with PPO FEV1 less than 40%
had a 35% survival rate compared with 65% in patients
with PPO FEV1 more than 40%.21
The 2013 Chest guideline recommends cardiopulmonary testing to determine patients’ exercise capacity
if either of their PPO FEV1 or DLCO is less than 30%.
Using a 40% cutoff for FEV1 and DLCO will give a PPO of
30% assuming a loss of 25% with resection. Figure 2A
and B illustrates the distribution of FEV1 and DLCO
among the patients selected by different criteria,
respectively. FEV1 less than 40% was present in 10%,
7%, and 7% of patients in USPSTF 2013, USPSTF 2021,
and NCCN gp 2 groups, respectively, which potentially
disqualify them for lung resection surgery. DLCO less
than 40% was present in 15%, 10%, and 10% of USPSTF
2013, USPSTF 2021, and NCCN gp 2 groups, respectively.
Hence, the USPSTF 2013 is more likely than other
criteria to select patients ineligible for lung resection
surgery.
The PLCOm2012 criteria, based on a logistic regression lung cancer risk prediction model that includes age,
smoking burden, and sociodemographic risk factors,
qualify a patient for screening on the basis of a risk
threshold of 1.51%/6 years.22 Patients reach the
threshold by being older, having a heavy smoking
burden, having COPD, or having certain sociodemographic risk factors. The recent CISNET lung cancer
simulation model revealed the equivalence of 1.70%
with USPST 2013 and 1.2% threshold with USPSTF
2021.23 We used the NLST-derived 1.51% threshold
which has been established for a longer time to allow
for generalizability with other published studies.22
Excluding the overlap with the USPSTF 2013 group,
the PLCOm2012 criteria tend to select an equally older
group of patients as the USPSTF 2013 which may pose a
problem with surgical outcomes. Mortality from thoracotomy increases with age. The 30-day mortality is as
low as 0.4% for patients younger than 60 years, goes up
to 2.0% for patients aged 70 to 79 years, and is as high
as 2.2% for those aged 80 years or older.24 Nonetheless,
the surgical approach for lung cancer resection is moving

JTO Clinical and Research Reports

Vol. 3 No. 8

away from open thoracotomy to thoracoscopic surgery
owing to the increasing acceptance that it offers similar
oncologic efﬁcacy and with fewer complications.25 The
use of thoracoscopic surgery halved the risk of postoperative
pneumonia
compared
with
open
thoracotomy.26
Overdiagnosis, which is the detection of an indolent
cancer that would not otherwise become clinically
apparent, is an inherent problem with lung cancer
screening. Approximately 18% of cancer detected in the
NLST was determined to be overdiagnosis, with most
being bronchioalveolar carcinoma (now reclassiﬁed).27,28 Nonetheless, the overdiagnosis rate decreases
to 3% on extended follow-up.29 Detection of patients
with such indolent cancer can artiﬁcially increase the
survival rates for lung cancer. Lead time bias occurs
because these patients are unlikely to die from the
cancer during the study period.16 The analysis of the
American College of Radiology Imaging Network cohort
of the NLST found that the excess cancer detected was
attributed to bronchioalveolar carcinoma that was
mainly in subjects without COPD rather than subjects
with COPD.30 This reveals that screening subjects with
COPD can result in more cancer detected per person
while minimizing overdiagnosis. In our study cohort,
among all the screening criteria, the PLCOm2012 ﬁts this
unique characteristic of having more patients with COPD
and at the same time only having mild to moderate
airﬂow limitation (FEV1 >50%). Nevertheless, the CISNET lung cancer simulation model indicates that risk
model-based criteria (PLCOm2012) shifted screening to
older age and that the criteria were more susceptible to
overdiagnosis compared with risk factor-based criteria
(USPSTF 2013).23
The inherent strength of our study is the use of a
cohort of patients with known lung cancer rather than a
large cohort of patients undergoing screening of whom
only a small fraction will develop cancer. This is because
ultimately it is the patients with lung cancer in whom
surgical ﬁtness matters. At the same time, the use of a
cohort of patients with known lung cancer to represent
the potential distribution of cardiopulmonary comorbidity of an actual lung cancer screening cohort has its
limitations. A patient may have a better PFT if the lung
cancer is diagnosed early by screening compared with
the cancer manifesting overtly at a more advance stage
allowing for the further decline in lung reserve especially
with continual cigarette exposure.
The USPSTF 2013 criteria are the most recommended
lung cancer screening criteria among the major organizations in the United States albeit with small differences
in the upper age limit. The introduction of USPSTF 2021
qualiﬁes a larger group of screening candidates who are
healthier with better lung reserve translating to better
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surgical candidacy. The PLCOm2012 guidelines, which
are known to have better accuracy in selecting patients
at risk of cancer, select an older group with COPD but
with still having good lung reserve.
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